APA

Engelbrechtsen L., Lundgren J., Wewer Albrechtsen N. J., Mahendran Y., Iepsen E. W., Finocchietto P., Jonsson A. E., Madsbad S., Holst J. J., Vestergaard H., Hansen T. & Torekov S. S. (122017). Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. : Obesity science & practice.

Chicago

Engelbrechtsen L, Lundgren J, Wewer Albrechtsen N J, Mahendran Y, Iepsen E W, Finocchietto P, Jonsson A E, Madsbad S, Holst J J, Vestergaard H, Hansen T and Torekov S S. 122017. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. : Obesity science & practice.

Harvard

Engelbrechtsen L., Lundgren J., Wewer Albrechtsen N. J., Mahendran Y., Iepsen E. W., Finocchietto P., Jonsson A. E., Madsbad S., Holst J. J., Vestergaard H., Hansen T. and Torekov S. S. (122017). Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. : Obesity science & practice.

MLA

Engelbrechtsen L, Lundgren J, Wewer Albrechtsen N J, Mahendran Y, Iepsen E W, Finocchietto P, Jonsson A E, Madsbad S, Holst J J, Vestergaard H, Hansen T and Torekov S S. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. : Obesity science & practice. 122017.